2014

1. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: Final results of the retreatment after herceptin adjuvant trial

   Clinical Oncology, Vol. 26, Núm. 2, pp. 81-89